Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2026)

Denali Therapeutics (DNLI) has reported Cash & Equivalents for 10 consecutive years, with $387.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 580.68% year-over-year to $387.6 million; the TTM figure through Mar 2026 stood at $387.6 million (up 580.68% YoY), while the FY2025 annual figure was $205.3 million, up 17.36% from the prior year.
• Cash & Equivalents improved to $387.6 million in Q1 2026 per DNLI's latest filing, from $205.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $387.6 million in Q1 2026 and bottomed at $56.9 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $138.5 million across 5 years, with a median of $127.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 75.89% — and 2026, when it jumped 580.68%.
• Denali Therapeutics' Cash & Equivalents stood at $218.0 million in 2022, then plunged by 41.71% to $127.1 million in 2023, then surged by 37.65% to $175.0 million in 2024, then increased by 17.36% to $205.3 million in 2025, then jumped by 88.79% to $387.6 million in 2026.
• Business Quant data shows DNLI's Cash & Equivalents at $387.6 million in Q1 2026, $205.3 million in Q4 2025, and $91.0 million in Q3 2025.